Evaluating the Cost-Effectiveness of Hydrogel Rectal Spacer in Prostate Cancer Radiotherapy
CONCLUSIONSBased on the current Medicare Physician Fee Schedule, HRS is cost-effective at a willingness to pay threshold of $100,000. These results contain substantial uncertainty, suggesting more evidence is needed to refine future decision making.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Clinical Trials | Colorectal Cancer | External Beam Therapy | Gastroenterology | Medical Devices | Medicare | Prostate Cancer | Radiation Therapy | Toxicology